Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia

Thomas Roberts; Grace Uwenedi; Rachel Bruton; Graham McIlroy; Sarah Damery; Panagiota Sylla; Nicola Logan; Sam Scott; May Lau; Ahmed Elzaidi; Siobhan Plass; Soumyajit Mallick; Katie Spencer; Christine Stephens; Christopher Bentley; Guy Pratt; Jianmin Zuo; Shankara Paneesha; Brian Willett; Paul Moss; Helen Parry

doi:10.1038/s41408-023-00940-5

Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia

Thomas Roberts, Grace Uwenedi, Rachel Bruton, Graham McIlroy, Sarah Damery, Panagiota Sylla, Nicola Logan, Sam Scott, May Lau, Ahmed Elzaidi, Siobhan Plass, Soumyajit Mallick, Katie Spencer, Christine Stephens, Christopher Bentley, Guy Pratt, Jianmin Zuo, Shankara Paneesha, Brian Willett, Paul MossHelen Parry^*

^*Corresponding author for this work

Research output: Contribution to journal › Letter › peer-review

10 Downloads (Pure)

Original language	English
Article number	22
Number of pages	3
Journal	Blood Cancer Journal
Volume	14
Issue number	1
DOIs	https://doi.org/10.1038/s41408-023-00940-5
Publication status	Published - 25 Jan 2024

Bibliographical note

Funding:
This work was partially supported by the UK Coronavirus Immunology Consortium. (UK-CIC) funded by DHSC/UKRI and the National Core Studies Immunity. Programme, UKRI award MC_UU_00034/6P. This is independent research was partly carried out at the National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the UK-CIC, UKRI, the NIHR or the Department of Health and Social Care. Sponsors had no role in the study design, collection, analysis, interpretation of the data or write up of the report.

Keywords

Humans
Leukemia, Lymphocytic, Chronic, B-Cell
COVID-19/prevention & control

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41408-023-00940-5Licence: Creative Commons: Attribution (CC BY)

RobertsT2024EnhancementFinal published version, 496 KBLicence: Creative Commons: Attribution (CC BY)

Cite this

Roberts, T., Uwenedi, G., Bruton, R., McIlroy, G., Damery, S., Sylla, P., Logan, N., Scott, S., Lau, M., Elzaidi, A., Plass, S., Mallick, S., Spencer, K., Stephens, C., Bentley, C., Pratt, G., Zuo, J., Paneesha, S., Willett, B., ... Parry, H. (2024). Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia. Blood Cancer Journal, 14(1), Article 22. https://doi.org/10.1038/s41408-023-00940-5

@article{628c5c8405094a7ebe144b90b969fc17,

title = "Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia",

keywords = "Humans, Leukemia, Lymphocytic, Chronic, B-Cell, COVID-19/prevention & control",

author = "Thomas Roberts and Grace Uwenedi and Rachel Bruton and Graham McIlroy and Sarah Damery and Panagiota Sylla and Nicola Logan and Sam Scott and May Lau and Ahmed Elzaidi and Siobhan Plass and Soumyajit Mallick and Katie Spencer and Christine Stephens and Christopher Bentley and Guy Pratt and Jianmin Zuo and Shankara Paneesha and Brian Willett and Paul Moss and Helen Parry",

note = "Funding: This work was partially supported by the UK Coronavirus Immunology Consortium. (UK-CIC) funded by DHSC/UKRI and the National Core Studies Immunity. Programme, UKRI award MC_UU_00034/6P. This is independent research was partly carried out at the National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the UK-CIC, UKRI, the NIHR or the Department of Health and Social Care. Sponsors had no role in the study design, collection, analysis, interpretation of the data or write up of the report.",

year = "2024",

month = jan,

day = "25",

doi = "10.1038/s41408-023-00940-5",

language = "English",

volume = "14",

journal = "Blood Cancer Journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

number = "1",

}

Roberts, T, Uwenedi, G, Bruton, R, McIlroy, G, Damery, S, Sylla, P, Logan, N, Scott, S, Lau, M, Elzaidi, A, Plass, S, Mallick, S, Spencer, K, Stephens, C, Bentley, C, Pratt, G, Zuo, J, Paneesha, S, Willett, B, Moss, P & Parry, H 2024, 'Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia', Blood Cancer Journal, vol. 14, no. 1, 22. https://doi.org/10.1038/s41408-023-00940-5

TY - JOUR

T1 - Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia

AU - Roberts, Thomas

AU - Uwenedi, Grace

AU - Bruton, Rachel

AU - McIlroy, Graham

AU - Damery, Sarah

AU - Sylla, Panagiota

AU - Logan, Nicola

AU - Scott, Sam

AU - Lau, May

AU - Elzaidi, Ahmed

AU - Plass, Siobhan

AU - Mallick, Soumyajit

AU - Spencer, Katie

AU - Stephens, Christine

AU - Bentley, Christopher

AU - Pratt, Guy

AU - Zuo, Jianmin

AU - Paneesha, Shankara

AU - Willett, Brian

AU - Moss, Paul

AU - Parry, Helen

N1 - Funding: This work was partially supported by the UK Coronavirus Immunology Consortium. (UK-CIC) funded by DHSC/UKRI and the National Core Studies Immunity. Programme, UKRI award MC_UU_00034/6P. This is independent research was partly carried out at the National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the UK-CIC, UKRI, the NIHR or the Department of Health and Social Care. Sponsors had no role in the study design, collection, analysis, interpretation of the data or write up of the report.

PY - 2024/1/25

Y1 - 2024/1/25

KW - Humans

KW - Leukemia, Lymphocytic, Chronic, B-Cell

KW - COVID-19/prevention & control

U2 - 10.1038/s41408-023-00940-5

DO - 10.1038/s41408-023-00940-5

M3 - Letter

C2 - 38272915

SN - 2044-5385

VL - 14

JO - Blood Cancer Journal

JF - Blood Cancer Journal

IS - 1

M1 - 22

ER -